Reported Earnings • May 10
First quarter 2026 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2025) First quarter 2026 results: US$0.16 loss per share (further deteriorated from US$0.12 loss in 1Q 2025). Revenue: US$265.0m (up 7.3% from 1Q 2025). Net loss: US$16.0m (loss widened 60% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance. 공시 • Apr 14
Eastman Kodak Company Announces Availability of Kodak Verita 200D Color Negative Motion Picture Film Eastman Kodak Company announces the availability of VERITA 200D 5206/7206, a new color negative motion picture film stock, which will be offered in 65mm, 35mm, and 16mm formats. Developed in close collaboration with writer, director and producer Sam Levinson and cinematographer Marcell Rév, HCA, ASC, VERITA 200D was commercialized in motion picture format to achieve a distinct visual aesthetic for the third season of HBO’s original drama series Euphoria. The stock has also been selectively trade-tested by cinematographers worldwide over several years. VERITA 200D delivers detailed highlights, high color saturation, deep blacks, and warm, natural skin tones. Compared with Kodak’s VISION3 color negative films, it features a shorter yet exceptionally rich dynamic range for a more classical cinematic look. Levinson and Rév exposed more than one million feet of VERITA 200D in 35mm and 65mm formats during production of Euphoria Season 3, which premiered April 12, 2026 on HBO and HBO Max, and was shot entirely on KODAK film. The series is also the first television production to shoot significant volumes of large-format 65mm film. Additionally, numerous commercials and music films utilized VERITA 200D in advance of its formal release as well as A24’s upcoming The Death of Robin Hood, directed by Michael Sarnoski, starring Hugh Jackman, and lensed by Pat Scola, ASC. In addition to recent advancements to VISION3 with a new anti-halation undercoat film structure, the commercialization of VERITA 200D underscores Kodak’s continued commitment to providing filmmakers with a variety of the highest-quality creative tools possible. As a specialty motion picture stock, VERITA 200D 5206/7206 is available by request through a Kodak sales representative. 공시 • Mar 13
Eastman Kodak Company, Annual General Meeting, May 20, 2026 Eastman Kodak Company, Annual General Meeting, May 20, 2026. Reported Earnings • Mar 13
Full year 2025 earnings released: US$1.47 loss per share (vs US$0.97 profit in FY 2024) Full year 2025 results: US$1.47 loss per share (down from US$0.97 profit in FY 2024). Revenue: US$1.07b (up 2.5% from FY 2024). Net loss: US$128.0m (down 264% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. 공시 • Jan 27
Eastman Kodak Company Expands Pharmaceuticals Portfolio with Four Regulated Products Eastman Kodak Company announced the expansion of its pharmaceuticals portfolio with four new regulated products: KODAK Phosphate Buffered Saline (PBS) 1X in low endotoxin and RNase/DNase/Protease-free formulations, and KODAK Water for Injection (WFI) in standard and RNase/DNase-free formulations. All are immediately available for order by U.S. research laboratories, Biopharma developers, and contract development and manufacturing organizations (CDMOs). The two new PBS formulations join a standard PBS 1X already shipping, while the WFI products represent the first offerings in that category. Customers gain the assurance of lot-traceable products built on Kodak's rigorous quality processes, including a multi-step water purification system that supports consistently high purity, along with responsive and personalized service. Kodak is working on additional regulated pharmaceuticals for introduction in the future. The new cGMP-compliant pharmaceuticals production facility in Rochester, N.Y. advances the organization's sustainability commitment through energy-efficient lighting and custom process equipment to reduce greenhouse gas emissions, plus a water sterilization system that minimizes consumption and waste. Kodak is in the process of applying for ISO 13485 certification for medical device quality management systems. 공시 • Nov 18
Eastman Kodak Company Announces Terry Taber Intends to Retire as Senior Vice President, Advanced Materials & Chemicals and Chief Technical Officer, Effective January 2, 2026 On November 14, 2025, Terry Taber, Senior Vice President, Advanced Materials & Chemicals and Chief Technical Officer, notified Eastman Kodak Company (“Kodak” or the “Company”) of his intention to retire, effective January 2, 2026. Mr. Taber has been a key contributor to Kodak for 45 years, playing a pivotal role in the Company’s technological innovation and growth. Throughout his distinguished career, Mr. Taber’s leadership and expertise have been instrumental in advancing Kodak’s research and development efforts, driving the success of the Advanced Materials & Chemicals division, and supporting the Company’s transformation through multiple eras of change. Following his retirement, Mr. Taber will continue to support Kodak through the transition of his duties and as a consultant for which he is expected to receive $25,000 per quarter as compensation for his services. 
